Short Interest in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Expands By 33.9%

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) was the target of a large growth in short interest in March. As of March 13th, there was short interest totaling 15,251 shares, a growth of 33.9% from the February 26th total of 11,389 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 18,725 shares, the short-interest ratio is presently 0.8 days.

Pharming Group Price Performance

PHAR stock traded down $0.30 during trading on Monday, hitting $16.01. The stock had a trading volume of 16,688 shares, compared to its average volume of 24,485. The stock has a market cap of $1.12 billion, a price-to-earnings ratio of 1,631.00 and a beta of 0.04. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.03 and a current ratio of 2.59. The company’s 50 day moving average price is $16.77 and its two-hundred day moving average price is $16.17. Pharming Group has a 1-year low of $7.50 and a 1-year high of $21.34.

Pharming Group (NASDAQ:PHAR) last issued its quarterly earnings results on Thursday, March 12th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.08). The firm had revenue of $106.50 million for the quarter, compared to analysts’ expectations of $111.76 million. Pharming Group had a return on equity of 1.08% and a net margin of 0.71%. On average, sell-side analysts forecast that Pharming Group will post -0.2 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on PHAR shares. Oppenheimer restated an “outperform” rating and set a $41.00 target price (down from $42.00) on shares of Pharming Group in a research report on Friday, March 13th. Wall Street Zen raised shares of Pharming Group to a “strong-buy” rating in a research note on Saturday, December 27th. HC Wainwright restated a “buy” rating and set a $37.00 price objective on shares of Pharming Group in a research report on Tuesday, March 24th. Weiss Ratings lowered Pharming Group from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, March 13th. Finally, Zacks Research cut Pharming Group from a “hold” rating to a “strong sell” rating in a report on Thursday, March 12th. Two investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $39.00.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. NewEdge Advisors LLC lifted its stake in shares of Pharming Group by 11,310.3% during the 4th quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock worth $510,000 after purchasing an additional 28,615 shares during the period. Millennium Management LLC acquired a new position in Pharming Group in the fourth quarter valued at $360,000. SmartHarvest Portfolios LLC purchased a new position in Pharming Group during the fourth quarter worth about $224,000. Finally, EverSource Wealth Advisors LLC purchased a new position in Pharming Group during the second quarter worth about $32,000. 0.03% of the stock is currently owned by institutional investors and hedge funds.

About Pharming Group

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.